228 related articles for article (PubMed ID: 12413342)
1. Perinatal outcome following third trimester exposure to paroxetine.
Costei AM; Kozer E; Ho T; Ito S; Koren G
Arch Pediatr Adolesc Med; 2002 Nov; 156(11):1129-32. PubMed ID: 12413342
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.
Oberlander TF; Misri S; Fitzgerald CE; Kostaras X; Rurak D; Riggs W
J Clin Psychiatry; 2004 Feb; 65(2):230-7. PubMed ID: 15003078
[TBL] [Abstract][Full Text] [Related]
3. Perinatal outcome following third-trimester exposure to paroxetine: an alternative interpretation.
Pryse-Phillips W; Yuen DE; Pham B
Arch Pediatr Adolesc Med; 2003 Jun; 157(6):601. PubMed ID: 12796244
[No Abstract] [Full Text] [Related]
4. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome?
Haddad PM; Pal BR; Clarke P; Wieck A; Sridhiran S
J Psychopharmacol; 2005 Sep; 19(5):554-7. PubMed ID: 16166193
[TBL] [Abstract][Full Text] [Related]
5. Paroxetine and neonatal withdrawal syndrome.
Pogliani L; Schneider L; Dilillo D; Penagini F; Zuccotti GV
BMJ Case Rep; 2010 Apr; 2010():. PubMed ID: 22736561
[TBL] [Abstract][Full Text] [Related]
6. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors.
Nordeng H; Lindemann R; Perminov KV; Reikvam A
Acta Paediatr; 2001 Mar; 90(3):288-91. PubMed ID: 11332169
[TBL] [Abstract][Full Text] [Related]
7. Neonate characteristics after maternal use of antidepressants in late pregnancy.
Källén B
Arch Pediatr Adolesc Med; 2004 Apr; 158(4):312-6. PubMed ID: 15066868
[TBL] [Abstract][Full Text] [Related]
8. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.
Levinson-Castiel R; Merlob P; Linder N; Sirota L; Klinger G
Arch Pediatr Adolesc Med; 2006 Feb; 160(2):173-6. PubMed ID: 16461873
[TBL] [Abstract][Full Text] [Related]
9. Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels.
Knoppert DC; Nimkar R; Principi T; Yuen D
Ther Drug Monit; 2006 Feb; 28(1):5-7. PubMed ID: 16418684
[TBL] [Abstract][Full Text] [Related]
10. [Neonatal withdrawal syndrome to selective serotonin reuptake inhibitors: case report and literature review].
Agut-Quijano T; Martínez-Nadal S; Elizari-Saco MJ; Sala-Castellví P; Vila-Cerén C; Raspall-Torrent F
Rev Neurol; 2006 Jun 1-15; 42(11):660-2. PubMed ID: 16736401
[TBL] [Abstract][Full Text] [Related]
11. Neonatal paroxetine withdrawal syndrome.
Stiskal JA; Kulin N; Koren G; Ho T; Ito S
Arch Dis Child Fetal Neonatal Ed; 2001 Mar; 84(2):F134-5. PubMed ID: 11207233
[TBL] [Abstract][Full Text] [Related]
12. [Neonatal convulsions and subarachnoid hemorrhage after in utero exposure to paroxetine].
Salvia-Roigés MD; Garcia L; Goncé-Mellgren A; Esqué-Ruiz MT; Figueras-Aloy J; Carbonell-Estrany X
Rev Neurol; 2003 Apr 16-30; 36(8):724-6. PubMed ID: 12717649
[TBL] [Abstract][Full Text] [Related]
13. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study.
Galbally M; Lewis AJ; Lum J; Buist A
Aust N Z J Psychiatry; 2009 Sep; 43(9):846-54. PubMed ID: 19670058
[TBL] [Abstract][Full Text] [Related]
14. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study.
Diav-Citrin O; Shechtman S; Weinbaum D; Wajnberg R; Avgil M; Di Gianantonio E; Clementi M; Weber-Schoendorfer C; Schaefer C; Ornoy A
Br J Clin Pharmacol; 2008 Nov; 66(5):695-705. PubMed ID: 18754846
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].
Favrelière S; Nourrisson A; Jaafari N; Pérault Pochat MC
Encephale; 2010 Jun; 36 Suppl 2():D133-8. PubMed ID: 20513456
[TBL] [Abstract][Full Text] [Related]
16. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health.
Warburton W; Hertzman C; Oberlander TF
Acta Psychiatr Scand; 2010 Jun; 121(6):471-9. PubMed ID: 19878137
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.
Kulin NA; Pastuszak A; Sage SR; Schick-Boschetto B; Spivey G; Feldkamp M; Ormond K; Matsui D; Stein-Schechman AK; Cook L; Brochu J; Rieder M; Koren G
JAMA; 1998 Feb; 279(8):609-10. PubMed ID: 9486756
[TBL] [Abstract][Full Text] [Related]
18. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.
Bérard A; Ramos E; Rey E; Blais L; St-André M; Oraichi D
Birth Defects Res B Dev Reprod Toxicol; 2007 Feb; 80(1):18-27. PubMed ID: 17187388
[TBL] [Abstract][Full Text] [Related]
19. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant.
Nordeng H; Spigset O
Drug Saf; 2005; 28(7):565-81. PubMed ID: 15963005
[TBL] [Abstract][Full Text] [Related]
20. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine.
Gentile S; Bellantuono C
J Clin Psychiatry; 2009 Mar; 70(3):414-22. PubMed ID: 19254517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
